Condition: Ann Arbor Stage II Follicular Lymphoma · Ann Arbor Stage II Marginal Zone Lymphoma · Ann Arbor Stage III Follicular Lymphoma · Sponsor: University of Washington
This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
This description comes directly from the study's public registry record.
Ajay Gopal · 206-606-2037 · agopal@uw.edu
Always discuss trial participation with your own doctor first.
| Fred Hutch/University of Washington Cancer Consortium | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06442475